In conclusion, our results suggest that changes in intra-tumor blood flow, AFP levels and remnant liver function after 2 weeks of sorafenib therapy may be useful for predicting outcomes and anti-tumor response in patients with advanced HCC. This evidence concerns the gene AFP and neoplasm.